Amalgamated Bank Has $20.52 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Amalgamated Bank lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.8% during the third quarter, HoldingsChannel reports. The firm owned 244,796 shares of the biopharmaceutical company’s stock after selling 7,062 shares during the quarter. Amalgamated Bank’s holdings in Gilead Sciences were worth $20,524,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. nVerses Capital LLC acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at $25,000. Valued Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares in the last quarter. CarsonAllaria Wealth Management Ltd. boosted its holdings in shares of Gilead Sciences by 198.3% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 238 shares in the last quarter. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at $33,000. Finally, Cedar Wealth Management LLC boosted its holdings in shares of Gilead Sciences by 51.6% in the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 160 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

GILD stock opened at $89.84 on Tuesday. The company has a market capitalization of $111.85 billion, a P/E ratio of 109.56, a price-to-earnings-growth ratio of 3.12 and a beta of 0.17. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $90.71. The business has a 50-day simple moving average of $84.05 and a two-hundred day simple moving average of $74.38.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. The business had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. Research analysts expect that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Raymond James raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective on the stock in a report on Monday, July 8th. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, October 9th. Royal Bank of Canada reissued a “sector perform” rating and set a $75.00 price objective on shares of Gilead Sciences in a report on Tuesday, October 29th. BMO Capital Markets raised their price objective on Gilead Sciences from $85.00 to $94.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Finally, Evercore ISI raised Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Ten analysts have rated the stock with a hold rating, eleven have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $86.85.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 36,847 shares of company stock worth $3,033,340. Insiders own 0.29% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.